Roswell Park Comprehensive Cancer Center

Survivin, an inhibitor of apoptosis protein, may be an attractive target for a variety of immunotherapeutic approaches for cancer, according to study results.

CHICAGO — Michael Ciesielski, PhD, assistant professor in the department of neurosurgery at Roswell Park Comprehensive Cancer Center, spoke with HemOnc Today at ASCO Annual Meeting about SurVaxM.

Two Children’s Oncology Group studies suggest progress has been made in the treatment of and survival outcomes for children and adolescents with Hodgkin lymphoma.

The combination of pembrolizumab and CMP-001, an intratumoral toll-like receptor 9 agonist, demonstrated antitumor activity among patients with metastatic melanoma resistant to PD-1 checkpoint inhibition, according to study results presented at American Association for Cancer Research Annual Meeting.

CHICAGO — Neoadjuvant therapy with the anti-PD-1 therapy nivolumab induced responses among nearly half of patients with resectable lung cancer, according to study results presented at American Association for Cancer Research Annual Meeting.

CHICAGO — The addition of the anti-PD-1 therapy pembrolizumab to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer who do not harbor EGFR or ALK alterations, according to results of the randomized phase 3 KEYNOTE-189 trial presented at American Association for Cancer Research Annual Meeting.

The Society for Immunotherapy of Cancer released the first set of consensus recommendations on the diagnosis and management of immune checkpoint inhibitor-related adverse events.

A clinical trial underway at Roswell Park Comprehensive Cancer Center is designed to assess the safety and efficacy of a two-pronged strategy that arms the immune system to more effectively attack cancer cells.

Multivitamin supplements may reduce incidence of chemotherapy-induced peripheral neuropathy among women undergoing treatment with paclitaxel for breast cancer, according to results of a study led by researchers at Roswell Park Comprehensive Cancer Center.

Since 2011, the FDA has approved six immune checkpoint inhibitors designed to reverse the course of multiple cancers.